Senior Correspondent, London
Ben's Feed
Nov 28, 2014
Nov 28, 2014

Germany’s Merck aims to grow, not sell $1 billion consumer health arm

LONDON (Reuters) – Merck KGaA (MRCG.DE: Quote, Profile, Research, Stock Buzz) aims to keep hold of its consumer healthcare unit, it said on Friday, pledging to develop a business that is expected to generate 2014 sales of $1 billion for the German drugs and chemicals company.

The non-prescription market has seen a wave of consolidation this year and a $17 billion deal for Merck to buy laboratory supplies business Sigma-Aldrich (SIAL.O: Quote, Profile, Research, Stock Buzz) has prompted some bankers to speculate it might consider selling the consumer unit.

Nov 26, 2014
Nov 26, 2014
Nov 26, 2014

Exclusive: First gene therapy drug sets million-euro price record

FRANKFURT/LONDON (Reuters) – The Western world’s first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.

The sky-high cost of Glybera, from Dutch biotech firm UniQure (QURE.O: Quote, Profile, Research, Stock Buzz) and its unlisted Italian marketing partner Chiesi, shows how single curative therapies to fix faulty genes may upend the conventional pharmaceutical business model.

Nov 25, 2014
Nov 24, 2014

EXCLUSIVE: Pay per puff? Caffeine stick? E-cigarette boom sparks race for new patents

LONDON (Reuters) – Electronic cigarette makers are racing to design and buy variations of a technology that has lit a billion-dollar boom, created a new vocabulary, and prompted a backlash from health officials worried about the impact of the new smokeless devices.

Research by Thomson Reuters shows that China – with over 300 million smokers – is the front runner in the manufacture and development of so-called e-cigarette technology, while new versions being patented include a “pay as you go” computer-assisted device and others that can deliver caffeine instead.

Nov 24, 2014

Exclusive – Pay per puff? Caffeine stick? E-cigarette boom sparks race for new patents

LONDON (Reuters) – Electronic cigarette makers are racing to design and buy variations of a technology that has lit a billion-dollar boom, created a new vocabulary, and prompted a backlash from health officials worried about the impact of the new smokeless devices.

Research by Thomson Reuters shows that China – with over 300 million smokers – is the front runner in the manufacture and development of so-called e-cigarette technology, while new versions being patented include a “pay as you go” computer-assisted device and others that can deliver caffeine instead.

Nov 18, 2014
Nov 18, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben